Former VP of New Product Commercialization and Speciality Products, Biogen Idec
Andrea Bruell, Former Vice President, New Product Commercialization and Specialty Products at Biogen Idec, was responsible for the company’s global commercial strategy for all pipeline assets, the global launch and marketing of treatments for specialty categories such as hemophilia, and the collaboration with Genentech/Roche on oncology products. She joined Biogen Idec in 2010 as VP, US Marketing where she established a new vision, transformed the culture, and delivered record-breaking sales performance for the company’s multiple sclerosis portfolio, including AVONEX, TYSABRI, and TECFIDERA. She also had accountability for the commercial diligence to support business development and M&A opportunities.
Prior to joining Biogen Idec, Ms. Bruell was Executive Director and Global Marketing Leader for the immunology franchise at Johnson & Johnson, responsible for the commercialization, launch readiness and life-cycle planning for J&J’s major new and emerging therapies. Earlier in her tenure with J&J, she led the global marketing of blockbuster drugs like TOPAMAX. From 1995-1999, Ms. Bruell was Director, Worldwide Strategic Product Development at GlaxoSmithKline where she was instrumental in driving the commercial strategy and launch plan for AVANDIA. Prior to GSK, she held brand marketing positions of increasing responsibility in specialty biologics.
Ms. Bruell has global and U.S. Commercialization experience across multiple therapeutic areas including rheumatology, endocrinology, neurology, hematology, and dermatology. Her track record includes successful launches of five specialty therapies, life-cycle management for emerging and marketed products, and strategic leadership in business development transactions and partnering initiatives.
Ms. Bruell earned a B.S. degree from Boston University and an MBA from Temple University. She also received a Graduate Fellowship for the M.S. Program in Business Communication from Cornell University.